Industry News

CND Life Sciences Secures Growth Financing to Expand Syn-One Test

CND Life Sciences announced the completion of growth financing led by S-Curve Partners, an operator-led healthcare investment firm focused on founder-inspired healthcare technology and diagnostics businesses. S-Curve was joined by current CND investors and shareholders, reflecting continued confidence in the Company’s commercial trajectory, expanding clinical adoption, and long-term strategic positioning. […]

Dental Sleep Medicine, Sleep Apnea

TAP Sleep Care Combination Therapy Delivers 95% AHI Reduction in Severe CPAP-Resistant OSA

TAP Sleep Care highlighted clinical evidence on Combination Therapy for CPAP-Resistant Obstructive Sleep Apnea from Martin A. Denbar, DDS, DABDSM, Diplomate of the American Board of Dental Sleep Medicine and Adjunct Assistant Professor in the Department of Internal Medicine at Texas A&M School of Medicine (Texas Dental Sleep Services). The […]

Industry News, Narcolepsy, Pharmacological, Sleep Disorders

U.S. FDA Approves Takeda’s ORZEYFUL (oveporexton), the First and Only Orexin Agonist for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. […]

Behavioral & Mental Health, Patient Health, Sleep Disorders

New Treatment Approach for Severe Sleep Disorders

Nightmares are among the most agonizing symptoms of post-traumatic stress disorder (PTSD) – a condition that can develop after exposure to severe traumatic experiences, such as disasters, serious accidents, acts of violence, or wartime experiences. Individuals affected relive the events intensely at night, as if they were real, time and […]